Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Down 99.3% in November

Nascent Biotech, Inc. (OTCMKTS:NBIO) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 100 shares, a drop of 99.3% from the November 15th total of 13,900 shares. Based on an average trading volume of 41,800 shares, the days-to-cover ratio is currently 0.0 days.

Nascent Biotech Price Performance

Nascent Biotech stock remained flat at $0.05 during midday trading on Friday. Nascent Biotech has a 12-month low of $0.03 and a 12-month high of $0.22. The firm’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.06.

Nascent Biotech Company Profile

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.